16:28 , Jun 27, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Animal models Mice with femoral implants could be used to model MRSA infection of orthopedic implants. The model involves implanting a titanium Kirschner wire in the intramedullary cavity of the femur of mice, then injecting...
08:00 , Nov 10, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Sepsis Staphylocoagulase precursor (coa); von Willebrand factor binding protein (vWbp); ClfA Mouse studies suggest inhibiting the...
07:00 , Mar 30, 2009 |  BC Week In Review  |  Company News

Inhibitex, 3M deal

3M returned to Inhibitex rights to develop diagnostics using Inhibitex's IP covering ClfA and additional MSCRAMM protein targets. Inhibitex said it has no plans to develop or license the technology and will continue to...
07:00 , Apr 16, 2007 |  BC Week In Review  |  Company News

FermaVir, Inhibitex deal

INHX will acquire FMVR in a stock-for-stock transaction. Each FMVR share will be exchanged for 0.55 shares of INHX stock, which values FMVR at about $19 million based on FMVR’s 20.8 million outstanding shares and...
08:00 , Jan 8, 2007 |  BC Week In Review  |  Company News

Inhibitex, 3M deal

MMM received an exclusive worldwide license to INHX's ClfA protein target for developing diagnostics. MMM also received a license to additional INHX MCSCRAMM protein targets, which are located on the surface of pathogenic organisms,...
07:00 , May 15, 2006 |  BC Week In Review  |  Clinical News

Aurexis: Phase I start

INHX will begin next quarter a U.S. Phase I study in 16 patients. Inhibitex Inc. (INHX), Atlanta, Ga.   Product: Aurexis   Business: Infectious   Molecular target: ClfA   Description: Humanized monoclonal antibody against ClfA surface protein...
07:00 , Apr 10, 2006 |  BC Week In Review  |  Clinical News

Veronate: Phase III data

Data from a double-blind, placebo-controlled, North American Phase III trial in 2,017 premature infants, weighing from 500 to 1,250 grams at birth, showed the compound missed the primary endpoint. There also were no trends in...
00:25 , Apr 4, 2006 |  BC Extra  |  Top Story

Inhibitex down on failed Phase III

On Monday, INHX fell $4.79 (66%) to $2.47 on 14.9 million shares after Veronate missed the primary endpoint of preventing hospital-acquired S. aureus infections in a Phase III trial in very low birth weight infants....
08:00 , Dec 12, 2005 |  BC Week In Review  |  Clinical News

Veronate: Phase III ongoing

INHX said that, for the fourth time, a DSMB recommended continuation of a double-blind, placebo-controlled Phase III trial of Veronate to prevent hospital-acquired infections in very low birth weight infants. The recommendation was based on...
08:00 , Nov 21, 2005 |  BC Week In Review  |  Clinical News

Veronate: Completed Phase III enrollment

INHX completed enrollment of 2,000 patients in a double-blind, placebo-controlled Phase III trial. Inhibitex Inc. (INHX), Atlanta, Ga.   Product: Veronate   Business: Infectious   Molecular target: ClfA   Description: Polyclonal antibody against microbial surface components recognizing adhesive...